7 results on '"Witzig, T.E."'
Search Results
2. External beam radiation therapy after 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory CD20+ non-Hodgkin’s lymphoma
3. Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin ®) Is a Safe and Effective Treatment Option for Older Patients with Relapsed or Refractory Low-Grade Non-Hodgkin’s Lymphoma (NHL)
4. Radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin) does not preclude subsequent radiotherapy or other antilymphoma therapies: Updated safety and efficacy data
5. Treatment with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy at first relapse in patients with B-cell non-Hodgkin’s lymphoma is associated with higher response rates and longer durations of response than as a more delayed treatment option: Results from a retrospective analysis
6. 2217 IDEC-Y2B8 ( 90YTTrium ibritumomab tiuxetan) radioimmunotherapy safety results in relapsed or chemotherapy refractory non-Hodgkin's lymphoma patients treated at reduced doses because of pre-existing thrombocytopenia
7. Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) Is a Safe and Effective Treatment Option for Older Patients with Relapsed or Refractory Low-Grade Non-Hodgkin’s Lymphoma (NHL)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.